However, trials of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated cardiovascular benefits in secondary prevention of major adverse cardiovascular events (MACE), including cardiovascular death, heart failure, stroke, and myocardial infarction (Vijan 2019). This evidence concerns the gene GLP1R and myocardial infarction.